Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTP (ID: DTQ23VB)

• DTP Name: Organic anion transporter 1 (SLC22A6) DTP Info
• Gene Name: OAT1

Molecule-Related Drug & Molecule List

23 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[1]
Adefovir	DMM278X	N. A.	N. A.	Approved	[2]
Alprostadil	DMWH7NQ	Aorta coarctation		Approved	[3]
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[4]
Cefaclor	DMJXDGC	Bacterial infection	1A00-1C4Z	Approved	[5]
Cefazolin	DMPDYFR	Bacteremia	1A73	Approved	[6]
Ceftizoxime	DM3VOGS	Acute gonococcal cervicitis		Approved	[5]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[7]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[8]
Famotidine	DMRL3AB	Gastric ulcer	DA60	Approved	[9]
FLUORESCEIN	DMQTFAO	Ocular disease	1F00.1Z	Approved	[10]
Furosemide	DMMQ8ZG	Congestive heart failure	BD10	Approved	[11]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[1]
MCI-186	DM8ZHP1	Amyotrophic lateral sclerosis	8B60.0	Approved	[12]
Meropenem	DM62UHC	Bacterial infection	1A00-1C4Z	Approved	[13]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[14]
Mycophenolic acid	DMRBMAU	Crohn disease	DD70	Approved	[15]
Olmesartan medoxomil	DMWBHRY	High blood pressure	BA00	Approved	[16]
Oseltamivir	DMGO72P	Influenza	1E30-1E32	Approved	[5]
Tenofovir	DM1IS6U	Chronic hepatitis B virus infection		Approved	[17]
Trifluridine	DMG2YBD	Herpetic keratitis	1F00.10	Approved	[18]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[19]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[1]

2 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dimesna	DMU4T9Y	Diabetic nephropathy	GB61.Z	Phase 3	[20]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[8]

5 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[21]
6-Carboxyfluorescein	DMWTMDH	N. A.	N. A.	Investigative	[22]
AMINOHIPPURIC ACID	DMUN54G	Discovery agent	N.A.	Investigative	[23]
GLUTARATE	DMPUFDS	Discovery agent	N.A.	Investigative	[22]
uric acid	DMA1MKT	Discovery agent	N.A.	Investigative	[24]

References

• [1] Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
• [2] Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000 Mar;11(3):383-93.
• [3] Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3. Prostaglandins Other Lipid Mediat. 2016 Jan;122:10-7.
• [4] The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
• [5] FDA Drug Development and Drug Interactions
• [6] Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
• [7] Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007 Apr;24(4):811-5.
• [8] Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
• [9] Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30.
• [10] Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
• [11] Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
• [12] Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate. Drug Metab Dispos. 2007 Aug;35(8):1429-34.
• [13] Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab Pharmacokinet. 2007 Feb 25;22(1):41-7.
• [14] Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
• [15] Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol. 2007 Jun 30;74(1):161-8.
• [16] Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
• [17] Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):641-8.
• [18] Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther. 2000 Sep;294(3):844-9.
• [19] Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
• [20] In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52(4):530-42.
• [21] Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35.
• [22] Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000 Jul 15;283(1):49-55.
• [23] Interactions of human organic anion transporter 1 (hOAT1) with substances associated with forensic toxicology. Leg Med (Tokyo). 2011 Jul;13(4):180-5.
• [24] Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008 Mar;25(3):639-46.